Izrael -
hebrejščina -
Ministry of Health
ספרייסל 50 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 50 mg - dasatinib
Izrael -
hebrejščina -
Ministry of Health
ספרייסל 70 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib
Izrael -
hebrejščina -
Ministry of Health
ספרייסל 100 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib
Izrael -
hebrejščina -
Ministry of Health
ספרייסל 20 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 20 mg - dasatinib
Izrael -
hebrejščina -
Ministry of Health
ספרייסל 50 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 50 mg - dasatinib
Izrael -
hebrejščina -
Ministry of Health
ספרייסל 70 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib
Izrael -
hebrejščina -
Ministry of Health
איקסמפרה 15 מ"ג
bristol-myers squibb (israel) limited - ixabepilone 15 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom futher anthracycline therapy is not indicated.
Izrael -
hebrejščina -
Ministry of Health
איקסמפרה 45 מ"ג
bristol-myers squibb (israel) limited - ixabepilone 45 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom further anthracycline therapy is not indicated.
Izrael -
hebrejščina -
Ministry of Health
זפוסיה 0.23 מג
bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.23 mg - ozanimod
Izrael -
hebrejščina -
Ministry of Health
זפוסיה 0.46 מג
bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.46 mg - ozanimod